OGFr Cancer Research Results

OGFr, Opioid Growth Factor Receptor: Click to Expand ⟱
Source:
Type:

OGFR - Opioid Growth Factor Receptor

Abbreviation: OGFR, OGFr

Alternative Names: Opioid Growth Factor Receptor, formerly Zeta Opioid Receptor

Type: Growth-regulatory receptor / nuclear-associated opioid growth factor receptor

Function: OGFr binds OGF and mediates the growth-inhibitory effects of the OGF-OGFr axis. The OGF-OGFr complex can traffic to the nucleus and regulate cyclin-dependent kinase inhibitory pathways, thereby delaying G1/S cell-cycle progression.

Cancer: ↓ Tumor-cell proliferation when OGFr signaling is intact. Increased OGFr expression can enhance responsiveness to OGF and suppress cancer-cell growth, whereas loss, mutation, or impaired trafficking of OGFr can reduce responsiveness to OGF-mediated growth inhibition.

Favorable Direction in Cancer: ↑ Functional OGFr expression/signaling is generally favorable because it strengthens OGF-mediated inhibition of proliferation.

Interpretation Note: OGFr is structurally distinct from classical opioid receptors and should not be grouped with OPRM1, OPRD1, or OPRK1.
Scientific Papers found: Click to Expand⟱
8341- LDN,    Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy
- Review, Var, NA
OGFr↑, TumCP↓, TumCCA↑, Apoptosis↑, toxicity↝, Half-Life↝, *FasL↓, *Fas↓, BAX↑, Casp9↑, Casp3↑, Bcl-2↓, survivin↓, PI3K↓, PDK1 / PDPK1↓, mTOR↓, ChemoSen↑, chemoP↑, eff↑, QoL∅,
8337- LDN,    Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway
- in-vitro, CRC, NA
OGFr↑, BAX↑, Casp9↑, Casp3↑, PARP↑, Bcl-2↓, survivin↓, Ki-67↓, Apoptosis↑,
8338- LDN,    Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway
- vitro+vivo, Cerv, HeLa - in-vitro, Cerv, SiHa
TumCP↓, TumCMig↓, TumCI↓, PI3K↓, p‑Akt↓, mTOR↓, OGFr↑, Dose↝, *toxicity↝, chemoP↑, ChemoSen↑,
8336- LDN,    Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin
- in-vivo, Ovarian, NA
Dose↝, ChemoSen↑, Weight↑, OGF↑, OGFr↑,
8335- LDN,    The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice
- vitro+vivo, Ovarian, SKOV3
OGF↑, OGFr↑, Dose↝, TumW↓, TumNum?, TumCP↓, angioG↓, toxicity↓,
8334- LDN,    Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model
- in-vitro, Ovarian, NA
OGFr↑, OGF↑,
8339- LDN,    Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo
- in-vivo, Cerv, HeLa
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, TAMS↓, M2 MC↓, IL10↓, OGFr↑, chemoP↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

OGF↑, 3,   OGFr↑, 7,   TumNum?, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

PDK1 / PDPK1↓, 1,  

Cell Death(tgid=5) ⓘ

p‑Akt↓, 1,   Apoptosis↑, 3,   BAX↑, 2,   Bcl-2↓, 2,   Casp3↑, 2,   Casp9↑, 2,   survivin↓, 2,  

DNA Damage & Repair(tgid=10) ⓘ

PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↓, 2,   PI3K↓, 2,  

Migration(tgid=13) ⓘ

Ki-67↓, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 4,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   TAMS↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL10↓, 1,   M2 MC↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 3,   Dose↝, 3,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 3,   QoL∅, 1,   toxicity↓, 1,   toxicity↝, 1,   TumW↓, 1,   Weight↑, 1,  
Total Targets: 34

Pathway results for Effect on Normal Cells:


Cell Death(tgid=5) ⓘ

Fas↓, 1,   FasL↓, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↝, 1,  
Total Targets: 3

Scientific Paper Hit Count for: OGFr, Opioid Growth Factor Receptor
7 low dose naltrexone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1808  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page